This study assessed reproductive performance, fetal viability and teratogenicity in female mice exposed to cyclophosphamide across a timeline corresponding to different stages of follicle maturation. Pregnancies were established in female Balb/c mice 1-4 weeks after administration of a non-sterilizing dose of cyclophosphamide (75 mg/kg). Each mating group represented a different stage of follicular growth at the time of cyclophosphamide exposure. The number of corpora lutea, pregnancies and fetal resorptions were determined. Surviving fetuses were evaluated for gross malformations. Results indicated that conceptions attributable to follicles exposed to cyclophosphamide at a mature stage had a significantly lower number of implantation sites, 4.82 ⍨ 1.01 versus 8.27 ⍨ 0.81 in controls (P ⍧ 0.001) and a high resorption rate, 56% ⍨ 0.11 versus 34% ⍨ 0.07 in controls (P ⍧ 0.05). The proportion of corpora lutea in this group which resulted in viable fetuses was extremely low, 0.2 ⍨ 0.06 versus 0.51 ⍨ 0.07 in controls (P ⍧ 0.001). Malformation rate was more than 10 times higher in all treated groups (P < 0.05) and a particularly high incidence of 33% (P ⍧ 0.0014) was observed in conceptions attributable to oocytes exposed to cyclophosphamide at the earliest stages of follicle growth. With an extended interval between exposure and mating the malformation rate gradually decreased towards normal values in the 12th week group. This study suggests that the effect of cyclophosphamide on female gametes and subsequently on future reproduction is influenced by the stage of oocyte maturation at the time of exposure. Early fertilization post-chemotherapy can result in a high rate of pregnancy failure and high malformation rate. This should be taken into account when considering the use of oocyte retrieval, IVF and embryo cryopreservation in patients currently undergoing chemotherapy.
Introduction
shown to cause primordial follicle destruction, and may, in high doses, result in adverse reproductive consequences, Cyclophosphamide is a commonly used chemotherapeutic and including premature menopause and sterility (Himelstein-Braw immunosuppressive agent for the treatment of a wide range et al., 1978; Apperley and Reddy, 1995; Meirow et al., 1997 ; of neoplastic diseases and some auto-immune diseases. With Chiarelli et al., 1999) . Moreover, animal studies have shown increased success of cancer treatment, due in part to the clear evidence that cyclophosphamide causes injury to germ aggressive use of high-dose combination drug therapies, there cells as well as induction of transmissible genetic damage has been growing concern about the long-term side-effects of (Generoso et al., 1971; Becker and Schoneich, 1982 ; Pdydn this alkylating agent and other antineoplastic drugs (Sutton and Ataya, 1991) , and this has raised serious concerns regarding et al Rodjer et al., 1990) .
the risk of abortions, birth defects, genetic or neoplastic disease Many studies have demonstrated that cyclophosphamide and in the offspring of cancer survivors who retain fertility after many other chemotherapeutic agents cause gene mutations, treatment. However, studies on pregnancy outcome in human chromosomal breaks and rearrangements, and aneuploidy in survivors of cancer treatment have suggested that such concerns somatic cells, as well as an increased frequency of secondary, are unfounded. Despite the observed increase in germ cell treatment-related tumours in human cancer survivors (Sandoval mutations, offspring of women exposed to cancer treatments et al., 1993; Povirk and Shuker, 1994; Ben-Yehuda et al., 1996) . In the gonads cyclophosphamide treatment has been do not have a greater than normal risk of chromosomal or congenital abnormalities (Hawkins, 1994; Sanders et al., 1996) . Materials and methods However, these data were collected from women who became Female inbred Balb/c mice (Harlan UK, Oxon, UK), 6-7 weeks pregnant a considerable time (often years) after cessation of of age (135 animals in total), were injected i.p. with 75 mg therapy. Thus, the lapse of a significant period of time between cyclophosphamide/kg body weight (ASTA Medica, Frankfurt, Germany). This dose was chosen based on a previous dose-response exposure to the mutagenic drugs and conception may enable study which showed that it reduced the ovarian primordial follicle the oocytes within the primordial follicles to instigate DNA reservoir by 50% without any effect on mating or pregnancy rate repair mechanisms to correct any genomic damage (Ashwood- (Meirow et al., 1999) . The females were housed separately until they Smith and Edwards, 1996) , or to be eliminated.
were introduced to proven fertile males of the same strain at a ratio With the advent of new reproductive technologies, centres of one male to a maximum of three females. Females were placed now offer patients the option of oocyte retrieval and embryo with males either 1, 2, 3 or 4 weeks post-cyclophosphamide treatment: cryopreservation before commencement of chemo/radiotherapy Table I . Mean number of implantations evaluated only for pregnant female. Resorption rate ϭ number of resorptions, i.e. non-viable fetuses/total number of implantation sites. a P values when compared with control group. for 12 days and then killed by cervical dislocation. It was decided to
Results
terminate the pregnancies after 12 days because at this stage it is still
The pregnancy rate in females mated 1 week after treatment possible to count the corpora lutea, allowing for assessment of the was 44% lower than 57-62% for all other females (Table I, number of ovulated oocytes, resorption sites from non-viable fetuses pregnant females a, b) (P ϭ not significant). No significant are visible, and the viable fetuses are developed enough to examine difference in mating rates in all groups was observed, also the for malformations. The uterus and both ovaries were removed and number of corpora lutea per female was similar (8-11) in all the following measurements taken: the number of corpora lutea were groups (Table II) . A high proportion of mice treated 1 week counted under the light binocular microscope, the numbers of viable and non-viable fetuses were noted, each conceptus was weighed before mating did not conceive despite the presence of corpora (including the placenta, membranes and amniotic fluid). Fetuses were lutea (ovulation), 18.5% compared with 2.9% of the controls dissected and inspected for gross anomalies under the light microscope and 3.3-6.9% of other treated groups (Table Ic) .
(magnification ϫ10-ϫ30). Those animals which did not show vaginal
In pregnant females an analysis was made of the different plugs were separated from males after 5 days, and killed 9 days later parameters of reproductive outcome. The presence and number (estimated to be approximately day 12 of pregnancy if conception of pregnancy sacs was evaluated, and these were categorized occurred midway through the 5 day mating period that is the average either as viable pregnancies, or non-viable-also termed length of an oestrous cycle). Where non-plugged mice did become resorbed pregnancies. The data on reproductive outcome are pregnant, all of the above parameters were examined except for the recorded in Tables II and III . The results indicated that the fetal weights, since the exact gestational age was unknown.
The data were grouped into three categories, based on the following group mated 1 week after chemotherapy exhibited poorest criteria (Table I) Cy. ϭ cyclophosphamide.
particular type of malformation occurred significantly more often than any other. These results indicate that pregnancies occurring shortly after chemotherapy are at high risk for malformations. A pronounced peak in the malformation rate was observed in fetuses conceived 3 weeks after cyclophosphamide treatment (34% Ϯ 9.4; P ϭ 0.0014). Thereafter a significant drop in malformation rate occurred in mice which had a 4 week interval between treatment and mating (17.5% Ϯ 5.6), possibly a sign of a recovery trend. In order to establish a critical period during which the effects of the treatment are most evident and to investigate this apparent recovery trend, mated 12 weeks after exposure (Figure 3 ). This appears to confirm a correlation between an extended time interval postpregnant females from the group mated 1 week after cyclophosexposure and a decrease in malformation rate. phamide showed the lowest proportion of corpora lutea which resulted in viable fetuses, 0.20 Ϯ 0.06 (Table II, The results presented here indicate that the effect of cyclophostreated groups.
phamide on female gametes and subsequently on future reproIn order to compare fetal weights, it was important to duction is time dependent and is influenced by the stage of consider the effect of litter size on any weight differences. To follicle development at the time of exposure. The full span of eliminate this bias, fetal weight was compared across three follicle development in this species is approximately 3 weeks subgroups, divided according to the total number of fetuses (Pedersen, 1970) . Oocytes exposed to chemotherapy as late present in the individual female as follows: 1-3, 4-6 and Ͼ7 pre-antral follicles (as represented by the group mated 1 fetuses. No significant difference between the various treated week following treatment) seem particularly vulnerable to groups and control group was detected in the mean fetal cyclophosphamide-induced lethal damage. As the results weights in any of the subgroups or overall (Table IV) . Fetal showed (Table I) , a larger proportion of mice treated 1 week weight, which fell below 90% confidence limits, was classified before mating were not pregnant at autopsy. This indicates as intrauterine growth retardation (IUGR), which occurred either failed fertilization, or preimplantation/implantation failsporadically regardless of litter size. A higher but non-significure and early resorption. In this group, females achieving ant rate of IUGR was observed in the mice mated 1 (10.3%) pregnancy had significantly fewer implantations and on day and 4 weeks (14.0%) after treatment compared with controls 12 of pregnancy exhibited significantly higher losses as represor other treatment groups (2.2-5.2%).
ented by higher resorption rate than in any other treated or Particularly significant was the increase in the incidence of control group (Table II) . These results might imply a particular malformations of all types observed in the offspring of mice vulnerability of oocytes at the later growth stages to genetic treated with cyclophosphamide The malformation rate in all or cytoplasmic lethal damage; however it could also partly be treated groups was at least 10 times higher than the rate (1.2% due to the debilitating effects of treatment on maternal physi-Ϯ 0.9) found in the control group (P Ͻ 0.05 for all groups). ology and health. It is less likely to be a result of poor uterine Several classes of malformations were observed including receptivity, since uterine or endometrial toxicity would have brain anomalies (affecting hind-, mid-and fore-brain), anteroaffected fetal weight and the data show no significant variation in fetal weights (Table IV) . posterior-axis aberrations, and limb abnormalities. No one hours (Genka et al., 1990) . This rise in fetal malformations peaking in week 3 and then decreasing again has also been observed in another animal study which looked at the malformation rate following treatment with radiation therapy . In that study the incidence of abnormalities and loss increased with the time interval between exposure and mating, peaking in animals treated 2-3 weeks before mating, followed by a significant decrease when the interval was between 3-4 weeks. Other studies (Brewen et al., 1976; Caine and Lyon, 1977; Russell, 1977) also bring evidence that conceptions occurring approximately 3 weeks after exposure are most vulnerable to the mutagenic effects of radiation. The ability of the oocyte to recover over time may explain the apparent contradiction between the increase in malformations shown in animal studies following recent exposure to chemo- ities or malformations. Until now, children of cancer therapy survivors were by necessity conceived a considerable length of time after cessation of treatment. Those conceptions resulted The higher rate of malformations observed across the groups from oocytes which had been exposed to therapy in a dormant treated (1-9 weeks), at least 10 times greater than that stage often years earlier (Hawkins, 1994) . seen in the control group, indicates that oocytes exposed to Significant numbers of cancer patients suffer infertility postcyclophosphamide during growing stages suffer from increased chemotherapy treatment. In order to preserve fertility, one of sublethal damage as a result of the teratogenic effects of the options available is to freeze-bank embryos, which involves cyclophosphamide. The increase in malformation rate was not follicle aspiration and IVF prior to chemotherapy administrathe same in all the groups. The results showed that the rate of tion (Apperley and Reddy, 1995) . Unfortunately, there are a malformations peaked in the group treated 3 weeks prior number of associated difficulties, which prevent widespread to mating (oocytes exposed as follicles just beginning the use of this procedure for cancer patients. Time is one of the maturation process). Thereafter malformation rate dropped major obstacles, since several weeks of monitoring and ovarian significantly in the group of mice treated 4, 6, and 9 weeks stimulation are often required, and in most cancer patients before mating and approached near normal levels at 12 weeks chemotherapy cannot be delayed. For this reason, some centres (Figure 3) . tend to offer IVF and embryo cryopreservation during a This would indicate that oocytes, which began the maturation suitable break in treatment (Brown et al., 1996) or during first process during chemotherapy treatment, were most susceptible remission prior to implementation of sterilizing protocols to non-lethal damage. The subsequent drop in malformation (Lipton et al., 1997) . rate following a critical period may be due to the ability of The safety of using IVF and embryo cryopreservation in oocytes to repair induced DNA damage (Ashwood-Smith and cancer patients who have recently undergone chemotherapy Edwards, 1996) . Another possible option for the reduction in treatments is questionable. These agents may cause mutations, malformation rate is that damaged oocytes were gradually lost DNA adducts and structural breaks as well as oxidative during the following weeks. Increased teratogenicity cannot damage. Therefore, concerns have been raised as to the quality be due to direct effects of cyclophosphamide on the fetus since the drug and its metabolites are cleared from the body within of embryos fertilized from oocytes harvested immediately
